Antibacterial, anti-biofilm and *in vivo* activities of the antimicrobial peptides P5 and P6.2

Melina Martínez, Axel Polizzotto, Naiquen Flores, Liliana Semorile, Paulo César Maffía

PII: S0882-4010(19)30601-1

DOI: https://doi.org/10.1016/j.micpath.2019.103886

Reference: YMPAT 103886

To appear in: Microbial Pathogenesis

Received Date: 11 April 2019

Revised Date: 22 October 2019 Accepted Date: 21 November 2019

Please cite this article as: Martínez M, Polizzotto A, Flores N, Semorile L, Maffía PauloCé, Antibacterial, anti-biofilm and *in vivo* activities of the antimicrobial peptides P5 and P6.2, *Microbial Pathogenesis* (2019), doi: https://doi.org/10.1016/j.micpath.2019.103886.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Ltd.



- 1 Antibacterial, anti-biofilm and in vivo activities of the antimicrobial
- 2 peptides P5 and P6.2
- 3 Melina Martínez^{1,2}, Axel Polizzotto¹, Naiquen Flores¹, Liliana Semorile¹, Paulo
- 4 César Maffía^{1,2}*
- 5 1. Laboratorio de Microbiología Molecular, Instituto de Microbiología Básica y
- 6 Aplicada, Universidad Nacional de Quilmes, Buenos Aires, Argentina
- 7 2. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
- 8 *Corresponding author: PhD. Maffía, Paulo César. Roque Sáenz Peña 352, B1876BXD
- 9 Bernal, Buenos Aires, Argentina. Tel: +54 11 4365-7017 ext. 5636. E-mail:
- 10 paulo.maffia@unq.edu.ar

ABSTRACT 12

13

14

15

16

17

18

20

22

23

24

25

26

27

28

29

Cationic antimicrobial peptides (AMPs) are short linear amino acid sequences, which display antimicrobial activity against a wide range of bacterial species. They are promising novel antimicrobials since they have shown bactericidal effects against multiresistant bacteria. Their amphiphilic structure with hydrophobic and cationic regions drives their interaction with anionic bacterial cytoplasmic membranes, which leads to their disruption. In this work two synthetic designed AMPs, P5 and P6.2, which 19 have been previously analyzed in their ability to interact with bacterial or eukaryotic membranes, were evaluated in their anti-biofilm and in vivo antibacterial activity. In a first step, a time-kill kinetic assay against P. aeruginosa and S. aureus and a curve for 21 hemolytic activity were performed in order to determine the killing rate and the possible undesirable toxic effect, respectively, for both peptides. The biofilm inhibitory activity was quantified at sub MIC concentrations of the peptides and the results showed that P5 displayed antibiofilm activity on both strains while P6.2 only on S. aureus. Scanning electron microscopy (SEM) of bacteria treated with peptides at their MIC revealed protruding blisters on Gam-negative P. aeruginosa strain, but almost no visible surface alteration on Gram-positive S. aureus. These micrographs highlighted different manifestations of the membrane-disrupting activity that these kinds of peptides possess. 30 Finally, both peptides were analyzed in vivo, in the lungs of neutropenic mice previously instilled with P. aeruginosa. Mice lungs were surgically extracted and 31 bacteria and pro-inflammatory cytokines (IL-β, IL-6 and TNF-α) were quantified by 32 33 colony forming units and ELISA, respectively. Results showed that instillation of the peptides produced a significant decrease in the number of living bacteria in the lungs, 34 concomitant with a decrease in pro-inflammatory cytokines. Overall, the results 35

presented here suggest that these two new peptides could be good candidates for future drug development for anti-biofilm and anti-infective therapy.

38

39

40 **Keywords:** antimicrobial peptides; Pseudomonas aeruginosa; anti-biofilm; anti-41 inflammatory; lung infection.

42

43

53

54

55

56

57

1. INTRODUCTION

Since their discovery many decades ago, antimicrobial peptides (AMPs) have been 44 proposed as potential new candidates for the development of novel antimicrobials [1–3]. 45 Their broad spectrum antimicrobial activity and selectivity make them attractive 46 candidates for novel drug compounds [4]. Although the potency of these AMPs against 47 48 the most sensitive pathogens is normally not as strong as certain conventional antibiotics, one of its major strengths is their ability to kill multi-drug-resistant bacteria 49 at relatively low concentrations. Compared with conventional antibiotics, the killing of 50 bacteria by AMPs is extremely rapid and can involve multiple bacterial cellular targets 51 [5]. 52

Besides their direct antimicrobial activity, AMPs are also increasingly being considered as novel agents against bacterial biofilms and also as immune-modulators of the host immune system. Regarding their anti-biofilm activity, AMPs are believed to inhibit the biofilm formation or to eradicate established ones [6,7]. Bacterial susceptibility to AMPs in biofilms has been shown to be lower compared to the planktonic state [8],

- however biofilm resistance to AMPs has not been extensively studied compared to other 58 antimicrobial agents [9,10]. 59 Finding new agents against bacterial biofilms has become an imperative task, since they 60 cause chronic infections with increased tolerance to antibiotics as well as resisting 61 phagocytosis. Particularly, biofilms produced by antibiotic resistant *P. aeruginosa* occur 62 at an elevated frequency both in medical devices and in lungs of Cystic Fibrosis (CF) 63 patients [9,11–13]. 64 Besides their antibacterial activity, the immune-modulatory properties of AMPs have 65 66 gained attention and many peptides are now known to modulate the innate immune response while suppressing potentially harmful inflammation [14]. It has been proposed 67 that some cationic host defense peptides like human cathelicidin LL-37 [15] or bovine 68 indolicidin [16] could induce a significant reduction of endotoxin-induced inflammatory 69 responses [14]. The anti-inflammatory properties of AMPs may be relevant in diseases 70 in which the exacerbated inflammation promotes cell damage and illness severity, like 71 72 the lung infections of patients with CF, in which Pseudomonas aeruginosa is a prominent pathogen. This bacterial species activates epithelial and immune cells which 73 74 results in the release of pro-inflammatory mediators [17,18]. 75 In previous works we have evaluated two novel synthetic cationic AMPs, P5 and P6.2, designed as amphipathic short alpha helical molecules, with affinity toward the 76 prokaryotic membranes rather than eukaryotic ones, and their structural characteristics 77 78 and membrane interactions have been analyzed [19-21]. Both peptides have been designed using a combined rational and computer assisted approach. Cationic alpha 79
 - databases. Then, these regions were combined or modified in order to have cationic

81

helical peptides were designed identifying short putative active regions from AMPs

amphipathic sequences with different physicochemical parameters [19]. P5 and P6.2 82 were selected from two different families of related peptides, in accordance to their 83 physicochemical performance and *in vitro* antimicrobial activity (Figure 1 and Table 1). 84 In this work, the biofilm inhibition activity of both peptides was analyzed in Gram-85 negative (P. aeruginosa PAO1) and Gram-positive (S. aureus ATCC25923) bacteria. 86 Scanning electron microscopy (SEM) was performed on *P. aeruginosa* and *S. aureus* 87 after treatment with peptides in order to visualize the possible membrane disruptive 88 activity these peptides have on Gram-negative and Gram-positive bacteria. 89 Both peptides were also analyzed in vivo, in the lungs of neutropenic mice previously 90 instilled with PAO1 and viable bacteria from the lungs were quantified to determine the 91

in vivo antimicrobial activity. Pro inflammatory cytokines (IL-1β, IL-6 and TNF-α)

levels were also measured in the extracted lungs in order to evaluate the possible anti-

95 **2 MATERIALS AND METHODS**

inflammatory activity.

2.1 Antimicrobial Peptides and bacterial strains

P5 and P6.2 are amphipathic cationic alpha helical antimicrobial peptides that were previously designed and analyzed [19,20,21]. P5 was selected from the related group of AMPs (P5, P8 and P8.1) [20] and P6.2 was selected from the P2, P6 and P6.2 group of related peptides [21]. Figure 1 depicts the helical wheel projection of the peptides, with their hydrophobic residues painted in yellow and their hydrophilic residues in blue. Table 1 shows the physicochemical parameters of each peptide, including the alpha helix content evaluated by circular dichroism in the presence of SDS micelles.

92

93

94

The bacterial strains used were *Pseudomonas aeruginosa* PAO1 and *Staphylococcus* aureus ATCC25923

2.2 Hemolytic activity

The hemolytic activity of peptides was assayed by a standard procedure [22,23]. In brief, fresh mice red blood cells (RBC) that were collected in the presence of heparin were washed three times in PBS. Peptides, dissolved in water, were added to the suspension of red blood cells (1% v/v in PBS) to a final volume of 200 μ l in a U bottom 96-well microplate. Then, samples were gently mixed, incubated at 37 °C for 1h and centrifuged for 10 min at 2000 rpm. The supernatant (100 μ l) from each well was transferred to a flat bottom 96-well plate, and the release of hemoglobin was measured by absorbance (Asample) at 540 nm. For negative and positive controls RBC in PBS (Ablank) or water (Awater) were used, respectively. The percentage of hemolysis was calculated according to the equation, Percentage of hemolysis = [(Asample - Ablank) / (Awater - Ablank)] x 100.

2.3 Time kill assay

Bactericidal activity of the peptides was evaluated using the time–kill assay. Growth-phase cultures in LB broth at 37°C were used for these experiments and the inoculum was adjusted by optical density. The assay was performed in 50 ml tubes, with a final volume of 10 ml of bacterial suspension in cation-adjusted Mueller–Hinton broth at a concentration of 5×10⁵ CFU/mL; each peptide was added at its MIC. Aliquots were removed at different time points in a 3-hour interval, and ten-fold dilutions of the samples were plated in LB agar plates. The CFU number was determined after 24 h of

plaque incubation at 37°C. A culture without AMPs was used as bacterial growth control. The reduction of 3 logarithmic units was considered bactericidal activity.

2.4 Scanning electron microscopy

Sample preparation for SEM was performed according to [24] with some modifications. *P. aeruginosa* PAO1 and *S. aureus* ATCC25923 bacterial cells were grown to exponential phase in LB broth. After centrifugation at 1,000 g for 10 min, the cell pellets were harvested, washed twice with PBS, and re-suspended to an optical density (OD 600) of 0.2. Cells were incubated at 37°C for 1 h with AMPs at their MICs. After incubation, the cells were centrifuged at 5,000 g for 5 min. The cell pellets were harvested, washed twice with PBS, and subjected to fixation with 2.5% glutaraldehyde at 4°C overnight, and then washed twice with PBS. The cells were then dehydrated in a graded ethanol series (50%, 70%, 90%, and 100%) for 10 min and in 100% acetone. Finally, the specimens were coated with gold and examined using a Carl Zeiss NTS SUPRA 40 instrument.

2.5 Biofilm quantification

Inhibition of biofilm development was assayed in 96-wells flat-bottom polystyrene plates. Antimicrobials were two fold serially diluted in Mueller Hinton broth and then the bacterial inoculum was added to reach a final concentration of $5x10^5$ CFU/ml, with a final volume of $100 \,\mu l$ per well. Plates were incubated at 37° C for 24 h. Media alone or media with inoculum were used as negative and positive control, respectively. The inoculum was prepared from an ON culture. After incubation, optic density at 595 nm was measured to quantify bacterial growth. To determine the amount of biofilm, after incubation the supernatant was gently removed and the formed biofilms were washed

twice with 100 μ l of saline solution to withdraw planktonic cells. The remaining biofilm was fixed with 100 μ l of 100% methanol for 15 minutes, and then stained with 100 μ l of crystal violet 1% (v/v) for 5 minutes. The dye was removed and washed twice with 200 μ l of distilled water, and the plate was dried at 37°C for 30 minutes. Finally, 100 μ l of 33% (v/v) acetic acid was added, samples were homogenized by gentle agitation and absorbance was measured in a microplate reader at 595nm.

2.5 Mice

Female BALB/c mice of 10-12 week of age were obtained from Bio Fucal S.A. (Argentina). All mice had access to food and water *ad libitum* and were used for studies of lung infection. Animals used in this study were followed for 1–5 days (4 animals per cage) to allow close observation from the beginning to end of each experiment. Feeding practices, light cycle, temperature, humidity, and cage and room cleaning procedures followed the regulations of this institution's central animal facility.

Ethic statement: All animal experiments complied with the Argentinian Government's animal experiment regulations and were approved by the Ethics Committee for Animal Experimentation of the National University of Quilmes (CICUAL), and were carried

2.6 Bacterial inoculum for infections

For mice infections, the *P. aeruginosa* PAO1 bacterial cells were grown ON in LB medium. Then, a fresh culture was prepared with 5% of the ON bacterial culture and incubated to reach an OD of 0.4. After centrifugation, the cell pellets were washed twice, re-suspended in saline solution and diluted to obtain a concentration of 8x10⁶

out in accordance with EU Directive 2010/63/EU for animal experiments.

bacteria/20 μl, which is the inoculum used for instillation. Inoculum was checked by
 plating on LB agar plates.

2.7 Induction of neutropenia

To obtain the neutropenic mice model, the cyclophosphamide protocol previously described in [25] was followed. Briefly, neutropenia was induced by i.p. cyclophosphamide (CP; Laboratorios Filaxis S.A, Argentina) on days -4 (at 200 mg/kg of body weight) and -1 (at 100 mg/kg) before infection and evaluated the day after the last CP injection. In order to corroborate the neutropenia, a complete hematological analysis was done. Blood was drawn from mice under anesthesia into tubes containing heparin (Northia, Argentina), using the retro-orbital plexus technique. Hematologic parameters were determined using a hematology analyzer in a veterinary clinical laboratory (Laboratorio Equino S.R.L, Argentina).

2.8 P. aeruginosa lung infection

Neutropenic mice were anesthetized intraperitoneally with ketamine/xylazine (100mg/kg; Holliday Scott S.A. / 10 mg/kg; PRO-SER S.A., Argentina) and 20 μ l of the bacterial solution were administrated directly into the nostrils. Thirty minutes after the infection, mice were treated with tobramycin, peptide or saline solution intranasally using an ultra-fine pipette tip. Mice were sacrificed 20 h after the infection and lungs surgically extracted.

2.9 Cytokine determination

- 201 Lung total weights were recorded and then they were disaggregated using a metal mesh.
- 202 Lung homogenates were prepared in 2 ml of sterile saline solution. Ten-fold serial

203	dilutions of homogenates were plated on LB agar plates, and CFU were counted after 20
204	h incubation at 37°C. IL-1β, IL-6 and TNF-α concentration in lung homogenates were
205	measured by ELISA (BD OptEIA Set; BD Biosciences) according to the manufacturer's
206	instructions (with detection limit at 10 ng/ ml).
207	
208	2.10 Statistical analysis
209	Statistical evaluation of differences between the experimental groups was determined by
210	using One-way ANOVA followed by Dunnett post test, with Graphpad Prism 5
211	software (GraphPad Software Inc., San Diego, CA). All data are presented as mean ±
212	standard error of the mean, and differences were considered to be statistically
213	significant at a <i>P</i> -value <0.05.
214	
215	
216	3 RESULTS
217	3.1 Antimicrobial and hemolytic activity
218	Table 2 shows the minimum inhibitory concentration (MIC) and the minimum
219	bactericidal concentration (MBC) for each peptide in P. aeruginosa PAO1 and S.
220	aureus ATCC25923.
221	In order to analyze the bactericidal effects of both peptides at different times, a time-kill
222	assay was performed (Figure 2A, B). The assay showed killing properties that are not
223	possible to observe in the MIC determination, like the rate of killing and the possible
224	bacteriostatic or bactericidal effect. The rate of killing of both peptides was remarkably

stronger in P. aeruginosa than in S. aureus. For P. aeruginosa, in 30 minutes P6.2

reduced more than 2 logarithmic units of CFU/ml and P5 completely eradicated

225

bacterial cells. On the contrary, for *S. aureus* the reduction of almost three logarithmic units was reached after 180 minutes and only P5 demonstrated bactericidal activity (99.9% of bacteria killed). In an attempt to gain insight into the possible undesirable effect toward erythrocyte membranes at different concentrations, we analyzed the hemolytic activity of each peptide in the range of 0-1024 µg/ml (Figure 2C). P5 displayed less than 10% hemolysis in all the range tested and P6.2 exhibited a concentration dependent hemolytic activity, reaching values of 30% at the highest concentration, but remaining below 5% until 128µg/ml, which is fourfold or eightfold the MIC obtained for *S. aureus* or *P. aeruginosa*, respectively.

3.2 Bacterial membrane disturbance by peptide interaction analyzed by scanning

electron microscopy (SEM)

In an attempt to visualize the possible effects these peptides may have on Gramnegative and Gram-positive bacteria, SEM was performed on *P. aeruginosa* and *S. aureus* treated with each peptide for 1 h at their MIC. The micrographs (Figure 3) showed that P5 and P6.2 produced surface alterations principally on *P. aeruginosa*, in which both peptides produced the formation of blisters or bubbles on the cell surface, revealing a possible direct interaction and destabilization of the bacterial membrane. On *S. aureus* the peptides at their MIC and for 1 hour incubation did not produced visible alterations on their surface, although a few bacterial cells began to shrink and some invaginations were visible.

3.3 Biofilm inhibition activity

- Both peptides were tested on their biofilm inhibition activity *in vitro* (figure 4 C and D).
- Bacterial growth inhibition at sub-MIC of peptides was also performed prior to biofilm

252	evaluation in order to determine whether the possible biofilm inhibition could be due
253	mainly to growth inhibition (figure 4 A and B).
254	P. aeruginosa and S. aureus were allowed to develop biofilm in the presence or absence
255	of each peptide at sub-MIC concentrations. Peptide P5 displayed significant inhibition
256	of biofilm at 0.5xMIC in both strains, but it did not show any activity at 0.25xMIC. On
257	the other hand, P6.2 displayed no inhibition activity in P. aeruginosa but showed anti
258	biofilm activity in S. aureus at both concentrations tested (figure 4C and 4D).
259	In S. aureus, the activity of P5 on biofilm inhibition could be related to the decrease in
260	bacterial growth on both concentrations; but for P6.2, although this peptide displayed a
261	similar growth inhibition than P5, the biofilm inhibition was higher, with statistical
262	significance in $0.5xMIC$ and $0.25x$ MIC compared to control. On the other hand, for P .
263	aeruginosa, P6.2 displayed growth inhibition but it did not inhibited biofilm formation
264	at all, like P5 did at 0.5xMIC. In the light of these results, it seems evident that there are
265	other mechanisms involved in biofilm inhibition, and that the growth inhibition is
266	neither sufficient nor indicative of the anti-biofilm activity that the AMP may have.
267	These results also highlight the differential activity these peptides display, regarding
268	Gram-negative or Gram-positive bacteria membrane and their biofilm characteristics.
269	
270	3.4 In vivo analysis of peptides
271	In order to analyze the in vivo activity of both peptides, we tested whether instilled P5
272	and P6.2 could diminish the bacterial burden in the lungs of neutropenic infected mice.
273	In order to have a suitable model for PAO1 lung infection, neutropenia was induced in
274	adult Balb/c mice.
275	

27

276

3.4.1 Neutropenic mice

Cyclophosphamide (CP), a well-known cytostatic and immunosuppressant drug, was used to induce neutropenia. In order to confirm neutropenia, a group of three mice treated with CP and a control immune competent group of three mice were evaluated analyzing circulating neutrophils, monocytes and lymphocytes. Table 3 shows the results obtained for each animal, as a percentage of total circulating cells. A significant decrease in the circulating neutrophils and monocytes was observed in the three mice treated with CP. No significant changes of body-weight was observed (data not shown) suggesting the absence of major CP-induced toxicity. Both peptides were instilled at 10mg/kg in neutropenic mice and no significant side effect was detected.

3.4.2 P. aeruginosa PAO1 instillation and lung bacteria recovery

Neutropenic mice were instilled with an inoculum of *P. aeruginosa* PAO1, and afterwards P5 or P6.2 were instilled. Twenty hours later, mice were sacrificed and lungs surgically extracted, processed and plated on LB agar for *P. aeruginosa* count. At the bacterial load used, the instillation of P5 or P6.2 at 10mg/kg reduced the bacterial load in mice lungs (figure 5A). P6.2 showed better performance *in vivo* than P5 because the first produced a more pronounced decrease in the bacterial load than the latter, in contrast to what it was seen *in vitro* in the time-kill assay or for antibiofilm activity.

A group of mice were instilled with tobramycin as control, and accordingly no bacteria

3.4.3 Pro inflammatory cytokines quantification

were recovered in the lungs.

Lungs of infected mice were processed and the pro inflammatory cytokines IL-1 β , IL-6 and TNF- α were quantified. Figure 5 shows that both peptides significantly decreased lung IL-1 β and IL-6 in neutropenic mice (figure 5 B and C) when administered

intranasally. TNF-α was also diminished (figure 5 D), although the differences between groups were less pronounced, probably because the peak time of this cytokine was reached earlier during this experiment. Control mice that received tobramycin after PAO1 instillation displayed the same cytokines' values as control uninfected mice.

306

302

303

304

305

DISCUSSION

307 308 We have previously designed a group of related cationic amphipathic alpha helical AMPs, and analyzed their physicochemical properties and interactions with bacterial or 309 eukaryotic membranes [19–21]. From these previous works, two peptides, P5 and P6.2 310 311 were selected for further anti biofilm and in vivo activity analysis. The time-kill assay showed that P5 displays a fast killing activity at its MIC on P. 312 aeruginosa, unlike P6.2 which possess a slower killing rate. However, as table 2 shows, 313 314 on this strain the MBC for both peptides is only 1 dilution more concentrated than the MIC. On the other hand, for S. aureus, both AMPs displayed a similar killing activity at 315 their MIC, and their MBC is two-fold more concentrated. 316 With the aim to visualize the effects of this kind of peptides on different bacterial 317 318 membranes, SEM images were performed after incubating P5 and P6.2 at their MIC for 319 1h with both strains. Micrographs revealed a clear alteration of P. aeruginosa 320 membrane integrity, evidenced by the presence of multiple bubbles or blisters on the cell surface. A similar phenomenon, although in a much less extent, has been reported 321 322 for other AMPs that share some structural and physicochemical features. The 323 appearance of blisters has been previously reported for the peptidyl-glycylleucinecarboxyamide (PGLa), which is a cationic amphipatic α-helical peptide of 21 amino 324 325 acids from the magainin family [24] and also for isoforms of the HE2 peptide [27]. As a possible explanation for these blisters it has been suggested that the positively charged 326

327	AMPs can substitute the Mg ²⁺ ions in the lipopolysaccharide layer on the outer
328	membrane of Gram-negative bacteria and thereby destabilize the outer surface [28].
329	Such destabilization of the outer membrane would promote the penetration of AMPs
330	and lead to a local disruption of the inner membrane, so that cytoplasmic material
331	locally fills the periplasmic space, which induces the formation of blisters without
332	disrupting the outer membrane.
333	On the other hand S. aureus did not show such visible membrane alteration, although
334	some cells treated with P5 showed holes or invaginations and a visible shrinkage. These
335	dents or holes seen on the surface of S. aureus cells are probably indicative of a
336	mechanical rupture of the membrane and cell wall. In any case it is worth to notice that
337	only a few Gram-positive cells treated with P5 displayed that evident membrane
338	rupture, unlike P. aeruginosa, where 100% of the cells showed bubble-like structures on
339	their surface. This phenomenon would probably be related to the different
340	characteristics of the cell wall of both strains. Gram-positive bacteria has a thick layer
341	of peptidoglycan on the surface that could mask the effects on the cell membrane.
342	Besides this evident difference between the strains, it is important to highlight that the
343	time of incubation (1 hour) and the concentration of the peptides (1xMIC) are still not
344	enough to see the complete lysis of the bacterial cells. For that reason what we are
345	seeing here is the whole bacterium, previous to complete membrane disruption.
346	Further SEM studies with increasing concentrations of AMPs at different times are
347	required in order to get a broader insight of the membranolytic activity of these
348	peptides.
349	Besides AMPs antimicrobial activity, it was suggested that AMPs have the potential to
350	act on multiple targets and stages of biofilm formation [29,30]. Some AMPs have been
351	reported to prevent biofilm formation and/or to eradicate established ones, and in some

352	cases the mechanisms beyond these anti-biofilm effects have been hypothesized [29,31].
353	It has been proposed that some peptides can interfere with the early events of biofilm
354	formation by preventing adhesion of bacterial cells to the substrate or to other cells, or
355	by killing cells before they stably become part of the biofilm architecture [32].
356	An increasing number of peptides show activity against biofilms at concentrations much
357	lower than their MIC, like LL-37 [29,33,34]. Particularly for this latter AMPs, that
358	shares some common features with the two AMPs analyzed here, Overhage and
359	coworkers [35] were able to demonstrate that LL-37 affects the development of biofilms
360	in at least three ways. First, the initial attachment of P. aeruginosa cells to the surface
361	was significantly reduced in the presence of LL-37; second, LL-37 promotes twitching,
362	by stimulating the expression of genes related to type IV pilus biosynthesis and
363	function; third, using microarray technology, they demonstrated that LL-37 affects the
364	two major quorum-sensing systems of P. aeruginosa, namely the Las and the Rhl
365	systems, by downregulating key components. Further detailed experiments would be
366	necessary to elucidate if P5 and P6.2 shares also these mode of action.
367	Alternatively, as it was proposed for the cationic AMP hep-20 [29], P5 and P6.2 due to
368	their cationic nature, could intercalate between the negatively charged bacterial cells
369	interfering with the interactions of matrix of extracellular polymeric substances (EPS)
370	components, thus reducing the amount of EPS that accumulates. In this work we report
371	the anti-biofilm activity of P5 and P6.2, at sub MIC concentrations. Besides their partial
372	growth inhibition, P5 displayed anti biofilm activity on both strains, P. aeruginosa and
373	S. aureus, while P6.2 was only active on S. aureus. Although both peptides displayed
374	some growth inhibiting activity at sub MIC concentration, inhibition of biofilm
375	production was diminished in some conditions. It is worth to notice that the production
376	of biofilm is not necessarily linked to the bacterial growth, at least in a certain growth

377	range. It can be seen that P6.2, for example, produced a 50% reduction in <i>P. aeruginosa</i>
378	growth at 0.5MIC, but the production of biofilm was still the same as the control, which
379	is an evidence of no anti-biofilm activity. On the other hand, also for <i>P. aeruginosa</i> , P5
380	displayed a 22% decrease in bacterial growth at 0.5xMIC, while it showed more than
381	42% biofilm inhibition at this concentration. Further experiments are required in order
382	to determine the specific mechanism by which these peptides (and other similar cationic
383	AMPs) affect, or not, biofilm formation beyond growth inhibition.
384	It is important to note that antibiotics at sub-optimal conditions promote biofilm
385	formation, probably because bacteria produce biofilm in an attempt to protect itself
386	from antimicrobial activity. For that reason, a major point for an antimicrobial agent is
387	that it can exhibit anti-biofilm activity at sub-MIC concentrations, which is not always
388	the case. Therefore, even though we are not able to elucidate the specific mechanism of
389	antibiofilm activity, it is remarkable that both peptides displayed biofilm inhibition at
390	sub-MIC concentrations.
391	P. aeruginosa is a cause of significant morbidity and mortality in hospitalized patients,
392	particularly those with compromised immune systems like neutropenic patients [36].
393	In this work P5 and P6.2 were tested in vivo, in the lungs of neutropenic mice
394	previosuly instilled with <i>P.aeruginosa</i> PAO1. In these experiments we analyzed the
395	total bacterial burden and the local levels of three pivotal inflammatory cytokines in
396	lung tissue homogenates upon P. aeruginosa PAO1 infection.
397	Upon instillation, P5 and P6.2 were capable to diminish the CFUs in lungs of
398	neutropenic mice. These results demonstrated that the peptides were still active in the
399	lungs of mice, and capable of killing bacteria in a pro inflammatory environment. It has
400	been shown that most cathelicidins are less active or do not have activity over Gram-

401 negative bacteria in physiological conditions, some exceptions are chCATH-1, and -2, PMAP-36 and PR-39[37]. 402 After peptides instillation, IL-1β and IL-6 were meaningfully diminished, while TNF-α 403 was diminished to a less extent, this could be explained in part because of the time 404 405 course of this cytokine in the lungs [38]. In fact TNF-α displays it peak at approximately 9 h post infection, and for the time the experiment was performed the 406 cytokine level could be naturally diminishing, which is reflected in the mild increase in 407 cytokine level between control uninfected mice and mice infected with PAO1. In that 408 scenario, although it seems to be a mild reduction, actually the peptides reversed the 409 cytokine concentration to the control levels. 410 The two novel designed AMPs, P5 and P6.2, besides reducing the bacterial load in the 411 lungs, significantly reduced the production of three pivotal inflammatory cytokines 412 upon acute lung infection in a neutropenic context. It is important to note that none of 413 the peptides completely eliminated the bacterial load in the lungs, as tobramycin did; 414 nevertheless the pro-inflammatory cytokines reduction was similar to this antibiotic. In 415 the case of tobramycin, the decrease in pro-inflammatory cytokines levels should be 416 417 expected as a result of the complete clearance of lung bacterial burden. In the case of P5 418 and P6.2 that did not completely eradicate bacteria from the lungs, the reduction in 419 cytokine levels should have another explanation. Further work will be required in order to unravel the mechanism beyond this down-regulation, but these results lead us to 420 421 believe that the peptides could be affecting the host cells, inducing the down regulation 422 of cytokines. Previous studies demonstrated that the cationic amphipathic AMP LL-37 has anti-423 424 inflammatory activity through various mechanisms, alter endotoxin aggregation through 425 LPS interactions [39] and in peripheral blood mononuclear cells strongly suppressed

426 synergistic responses to TREM-1 and TLR4 stimulation, partly through the inhibition of TREM-1 expression on monocytes [40]. Another example is chCATH-2 (chicken 427 cathelicidin-2), it has been shown that chCATH-2-mediated killing of P. aeruginosa 428 inhibits pulmonary inflammation in a mouse lung model by reducing PMN recruitment 429 430 and preventing the release of pro-inflammatory cytokines and chemokines [41–43]. Inflammation is essential for host defense, but a failure to tightly control immune 431 432 responses to a pathogen can result in chronic inflammation and tissue destruction. It is worth to notice that the pathophysiological mechanisms of pneumonia-induced sepsis 433 include a surge of pro-inflammatory cytokines. In fact IL-1 β plays important roles in the 434 up- and down-regulation of acute inflammation [44] but it can also functions as a 435 mediator of chronic inflammation and promotes fibrosis. In this work we showed that 436 these new alpha helical cationic peptides might be suitable candidates for the 437 438 development of potential anti-biofilm and anti-infective drugs, to be used for instance for CF therapies, with both antimicrobial and anti-inflammatory functions. 439

440

441

442

443

5 COMPLIANCE WITH ETHICS GUIDELINES

Melina Martínez, Axel Polizzotto, Liliana Semorile and Paulo César Maffía declare that they have not conflict of interest.

444

445

6 ACKNOWLEDGEMENT

This work was supported by grants from Agencia Nacional de Promoción Científica y

Tecnológica (PICT 0478 – 2016) and Universidad Nacional de Quilmes (Proyectos

Orientados Práctica Profesional and Programa Microbiología Molecular Básica y

Aplicada). PM is a member of the Research Career of CONICET (National Scientific

and Technical Research Council, Argentina). LS is a member of the Research Career of

451	Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-BA),
452	MM is a doctoral fellow of CONICET.
453	We appreciate Dr. Elizabeth Tymczyszyn for her invaluable help with statistical
454	analysis.
455	The funders had no role in study design, data collection and analysis, decision to
456	publish, or preparation of the manuscript.
457	
458	
459	

Peptide	MW*	lp*	NC**	μΗ**	H**	AC
P 5	2356.98	11.26	7	0.58	0.455	88%
P 6.2	2515.09	11.75	7	0.793	0.328	46%

Table 1 – Physicochemical parameters analyzed *in silico* and experimentally for P5 and P6.2. MW: molecular weight (daltons), Ip: isoelectric point, NC: net charge, μ H: hydrophobic moment, H: hidrophobicity, AC: alpha helix content. The percent helix values were determined based on circular dichroism spectra calculated as the mean residue molar ellipticity at 222 nm, in SDS micelles.

** http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParamsV2.py

	P. aeru	eginosa	S. aure	us
	P5	P6.2	P5	P6.2
MIC	64	16	16	32
MBC	128	32	64	128


Table 2. MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) on *P. aeruginosa* and *S. aureus* for both peptides expressed in μ g/ml.

Samples	Neutrophils (%)	Lymphocytes (%)	Monocytes (%)
1) Neutropenic	4	96	0
2) Neutropenic	2	98	0
3) Neutropenic	3	97	0
4) Control	25	74	1
5) Control	30	69	1
6) Control	32	66	2

Table 3 - Effect of I.P injected cyclophosphamide on Balb/c mice

^{*} http://web.expasy.org/compute_pi/

484 Figures






Figure 1. Helical wheel projection diagrams of the peptides, depicting the residues and their relative position in the alpha helix. Yellow circles represent hydrophobic residues and blue circles the positively-charged aminoacids, uncharged residues are painted in pink (Gln) and grey (Gly), and negatively charged residues (Glu) in red. The arrow depicts the hydrophobic moment. Left panel P6.2, right panel P5.




Figure 2. Killing kinetics with *P. aeruginosa* (A) and *S. aureus* (B). Each peptide was incubated at their MIC with approximately 5×10^5 CFU/ml inoculum. Samples were taken at different intervals for three hours, plated and viable CFUs counted by triplicate. C) Hemolytic activity of P5 and P6.2 at different concentrations. Mouse erythrocytes were incubated for 1h with AMPs and trelease of hemoglobin was determined by measuring the absorbance at 540 nm.




Figure 3. Scanning electron microscopy (SEM) of *P. aeruginosa* and *S. aureus*. Bacterial cells were incubated with P5 or P6.2 for 1 hour at 37°C at their MIC. A) *P. aeruginosa* with no treatment. B) *S. aureus* with no treatment. C) *P. aeruginosa* treated with P5 D) *S. aureus* treated with P5 E) *P. aeruginosa* treated with P6.2 F) *S. aureus* treated with P6.2




Figure 4. Bacterial growth and biofilm quantification. A, B) Bacterial growth of *P. aeruginosa* and *S. aureus* incubated with P5 or P6.2 at sub MIC concentrations. GC growth control with no antibiotic. C, D) Biofilm quantification. The total amount of biomass of *P. aeruginosa* and *S. aureus* incubated with P5 or P6.2 at sub MIC concentrations was quantified with crystal violet. One Way ANOVA - Dunnett's Multiple Comparison Test *p<0.05, **p<0.01, ***p<0.001 against GC (growth control) or C+ (positive control with no antibiotic)




Figure 5. A) Total colony forming units (CFU) in the lung of infected neutropenic mice. Each mouse was intranassally infected with an inoculum of 10⁶ CFU PAO1 and subsequently instilled with saline (PAO1), P6.2 (PAO1+P6.2), P5 (PAO1+P5) or tobramycin (PAO1+tobra). A group of mice were not infected and received saline (Control). After 20 h animals were sacrificed and their lungs surgically extracted and processed for viable bacteria counting. B, C, D) Cytokine quantification. ELISA was performed on the processed lungs samples to quantified pro inflammatory cytokines. Dunnett's Multiple Comparison Test, *p<0.05, **p<0.01, ***p<0.001, compared to PAO1

	1	c
2	Z	σ

D	- C -			
ĸ	efe	re	ու	PC

527	Refe	erences
528	[1]	B. Gomes, M.T. Augusto, M.R. Felício, A. Hollmann, O.L. Franco, S.
529		Gonçalves, N.C. Santos, Designing improved active peptides for therapeutic
530		approaches against infectious diseases, Biotechnol. Adv. (2018).
531		doi:10.1016/j.biotechadv.2018.01.004.
532	[2]	MD. Seo, HS. Won, JH. Kim, T. Mishig-Ochir, BJ. Lee, Antimicrobial
533		Peptides for Therapeutic Applications: A Review, Molecules. (2012).
534		doi:10.3390/molecules171012276.
535	[3]	A.K. Marr, W.J. Gooderham, R.E. Hancock, Antibacterial peptides for
536		therapeutic use: obstacles and realistic outlook, Curr. Opin. Pharmacol. (2006).
537		doi:10.1016/j.coph.2006.04.006.
538	[4]	A. Hollmann, M. Martinez, P. Maturana, L.C. Semorile, P.C. Maffia,
539		Antimicrobial peptides: Interaction with model and biological membranes and
540		synergism with chemical antibiotics, Front. Chem. 6 (2018).
541		doi:10.3389/fchem.2018.00204.
542	[5]	K.A. Brogden, Antimicrobial peptides: Pore formers or metabolic inhibitors in
543		bacteria?, Nat. Rev. Microbiol. (2005). doi:10.1038/nrmicro1098.
544	[6]	L. Grassi, G. Maisetta, G. Maccari, S. Esin, G. Batoni, Analogs of the Frog-skin
545		Antimicrobial Peptide Temporin 1Tb Exhibit a Wider Spectrum of Activity and a
546		Stronger Antibiofilm Potential as Compared to the Parental Peptide, Front.
547		Chem. (2017). doi:10.3389/fchem.2017.00024.
548	[7]	L.J. Bessa, P. Eaton, A. Dematei, A. Placido, N. Vale, P. Gomes, C. Delerue-
549		Matos, J.R.S.A. Leite, P. Gameiro, Synergistic and antibiofilm properties of

ocellatin peptides against multidrug-resistant Pseudomonas aeruginosa, Future

- 551 Microbiol. (2018). doi:10.2217/fmb-2017-0175C.
- 552 [8] A. Folkesson, J.A.J. Haagensen, C. Zampaloni, C. Sternberg, S. Molin, Biofilm
- induced tolerance towards antimicrobial peptides, PLoS One. (2008).
- doi:10.1371/journal.pone.0001891.
- R. Nuri, T. Shprung, Y. Shai, Defensive remodeling: How bacterial surface
- properties and biofilm formation promote resistance to antimicrobial peptides,
- Biochim. Biophys. Acta Biomembr. (2015).
- 558 doi:10.1016/j.bbamem.2015.05.022.
- 559 [10] V. Luca, A. Stringaro, M. Colone, A. Pini, M.L. Mangoni, Esculentin(1-21), an
- amphibian skin membrane-active peptide with potent activity on both planktonic
- and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa, Cell. Mol.
- 562 Life Sci. (2013). doi:10.1007/s00018-013-1291-7.
- 563 [11] Y. Lequette, E.P. Greenberg, Timing and localization of rhamnolipid synthesis
- gene expression in Pseudomonas aeruginosa biofilms, in: J. Bacteriol., 2005.
- doi:10.1128/JB.187.1.37-44.2005.
- 566 [12] E. Drenkard, F.M. Ausubel, Pseudomonas biofilm formation and antibiotic
- resistance are linked to phenotypic variation, Nature. (2002).
- 568 doi:10.1038/416740a.
- 569 [13] C. De la Fuente-Núñez, F. Reffuveille, L. Fernández, R.E.W. Hancock, Bacterial
- 570 biofilm development as a multicellular adaptation: Antibiotic resistance and new
- therapeutic strategies, Curr. Opin. Microbiol. (2013).
- 572 doi:10.1016/j.mib.2013.06.013.
- 573 [14] N. Mookherjee, R.E.W. Hancock, Cationic host defence peptides: Innate immune
- regulatory peptides as a novel approach for treating infections, Cell. Mol. Life
- 575 Sci. (2007). doi:10.1007/s00018-007-6475-6.

- 576 [15] N. Mookherjee, L.M. Rehaume, R.E. Hancock, Cathelicidins and functional
- analogues as antisepsis molecules, Expert Opin. Ther. Targets. (2007).
- 578 doi:10.1517/14728222.11.8.993.
- 579 [16] A. Giacometti, O. Cirioni, R. Ghiselli, F. Mocchegiani, M.S. Del Prete, C.
- Viticchi, W. Kamysz, E. Łempicka, V. Saba, G. Scalise, Potential therapeutic
- role of cationic peptides in three experimental models of septic shock,
- 582 Antimicrob. Agents Chemother. (2002). doi:10.1128/AAC.46.7.2132-2136.2002.
- 583 [17] F. Seiler, C. Beisswenger, F. Langer, J. Hellberg, M. Bischoff, R. Bals, F.
- Lammert, A. Kamyschnikow, P.M. Lepper, H.-J. Schafers, M.D. Menger, C.
- Herr, FOXO Transcription Factors Regulate Innate Immune Mechanisms in
- Respiratory Epithelial Cells, J. Immunol. (2013).
- 587 doi:10.4049/jimmunol.1200596.
- 588 [18] T.J. Bensman, J.G. Jayne, M. Sun, E. Kimura, J. Meinert, J.C. Wang, J.B. Schaal,
- D. Tran, A.P. Rao, O. Akbari, M.E. Selsted, P.M. Beringer, Efficacy of Rhesus
- Theta-Defensin-1 in Experimental Models of <span class="named-
- content genus-species" id="named-content-
- 1">Pseudomonas aeruginosa Lung Infection and
- Inflammation, Antimicrob. Agents Chemother. 61 (2017) e00154-17.
- 594 doi:10.1128/AAC.00154-17.
- 595 [19] D. Faccone, O. Veliz, A. Corso, M. Noguera, M. Martínez, C. Payes, L.
- Semorile, P.C. Maffía, Antimicrobial activity of de novo designed cationic
- 597 peptides against multi-resistant clinical isolates, Eur. J. Med. Chem. 71 (2014).
- 598 doi:10.1016/j.ejmech.2013.10.065.
- 599 [20] A. Hollmann, M. Martínez, M.E. Noguera, M.T. Augusto, A. Disalvo, N.C.
- Santos, L. Semorile, P.C. Maffía, Role of amphipathicity and hydrophobicity in

501		the barance between nemotysts and peptide-memorane interactions of three
502		related antimicrobial peptides, Colloids Surfaces B Biointerfaces. 141 (2016).
503		doi:10.1016/j.colsurfb.2016.02.003.
504	[21]	P. Maturana, M. Martinez, M.E. Noguera, N.C. Santos, E.A. Disalvo, L.
505		Semorile, P.C. Maffia, A. Hollmann, Lipid selectivity in novel antimicrobial
506		peptides: Implication on antimicrobial and hemolytic activity, Colloids Surfaces
507		B Biointerfaces. 153 (2017). doi:10.1016/j.colsurfb.2017.02.003.
508	[22]	Z. Oren, Y. Shai, Selective lysis of bacteria but not mammalian cells by
509		diastereomers of melittin: Structure-function study, Biochemistry. (1997).
510		doi:10.1021/bi9625071.
511	[23]	C. Subbalakshmi, R. Nagaraj, N. Sitaram, Biological activities of C-terminal 15-
512		residue synthetic fragment of melittin: Design of an analog with improved
513		antibacterial activity, FEBS Lett. (1999). doi:10.1016/S0014-5793(99)00328-2.
514	[24]	W. Hong, X. Gao, P. Qiu, J. Yang, M. Qiao, H. Shi, D. Zhang, C. Tian, S. Niu,
515		M. Liu, Synthesis, construction, and evaluation of self-assembled nano-bacitracin
516		a as an efficient antibacterial agent in vitro and in vivo, Int. J. Nanomedicine.
517		(2017). doi:10.2147/IJN.S136998.
518	[25]	D. Jabés, C. Brunati, G.P. Candiani, S. Riva, G. Romanó, S. Donadio, Efficacy of
519		the new lantibiotic NAI-107 in experimental infections induced by multidrug-
520		resistant gram-positive pathogens, Antimicrob. Agents Chemother. (2011).
521		doi:10.1128/AAC.01288-10.
522	[26]	M. Hartmann, M. Berditsch, J. Hawecker, M.F. Ardakani, D. Gerthsen, A.S.
523		Ulrich, Damage of the bacterial cell envelope by antimicrobial peptides
524		gramicidin S and PGLa as revealed by transmission and scanning electron
525		microscopy, Antimicrob. Agents Chemother. (2010). doi:10.1128/AAC.00124-

10. 626 S. Yenugu, K.G. Hamil, F.S. French, S.H. Hall, Antimicrobial actions of the 627 human epididymis 2 (HE2) protein isoforms, HE2alpha, HE2beta1 and 628 629 HE2beta2, Reprod. Biol. Endocrinol. (2004). doi:10.1186/1477-7827-2-61. A. Da Silva, O. Teschke, Effects of the antimicrobial peptide PGLa on live 630 [28] Escherichia coli, Biochim. Biophys. Acta - Mol. Cell Res. (2003). 631 632 doi:10.1016/j.bbamcr.2003.10.001. G. Batoni, G. Maisetta, S. Esin, Antimicrobial peptides and their interaction with [29] 633 biofilms of medically relevant bacteria, Biochim. Biophys. Acta - Biomembr. 634 (2016). doi:10.1016/j.bbamem.2015.10.013. 635 G. Batoni, F. Lisa Brancatisano, M. Campa, G. Maisetta, S. Esin, Use of 636 [30] Antimicrobial Peptides Against Microbial Biofilms: Advantages and Limits, 637 Curr. Med. Chem. (2011). doi:10.2174/092986711794088399. 638 M. di Luca, G. Maccari, R. Nifosí, Treatment of microbial biofilms in the post-639 640 antibiotic era: Prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools, Pathog. Dis. (2014). doi:10.1111/2049-641 632X.12151. 642 643 [32] L. Segev-Zarko, R. Saar-Dover, V. Brumfeld, M.L. Mangoni, Y. Shai, 644 Mechanisms of biofilm inhibition and degradation by antimicrobial peptides, Biochem. J. (2015). doi:10.1042/bj20141251. 645 646 [33] J. Overhage, A. Campisano, M. Bains, E.C.W. Torfs, B.H.A. Rehm, R.E.W. Hancock, Human host defense peptide LL-37 prevents bacterial biofilm 647 formation, Infect. Immun. (2008). doi:10.1128/IAI.00318-08. 648 649 [34] C. Nagant, B. Pitts, K. Nazmi, M. Vandenbranden, J.G. Bolscher, P.S. Stewart,

J.P. Dehaye, Identification of peptides derived from the human antimicrobial

651		peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using
652		a library of truncated fragments, Antimicrob. Agents Chemother. (2012).
653		doi:10.1128/AAC.00918-12.
654	[35]	J. Overhage, A. Campisano, M. Bains, E.C.W. Torfs, B.H.A. Rehm, R.E.W.
655		Hancock, Human host defense peptide LL-37 prevents bacterial biofilm
656		formation, Infect. Immun. (2008). doi:10.1128/IAI.00318-08.
657	[36]	D. Annane, P. Aegerter, M.C. Jars-Guincestre, B. Guidet, Current epidemiology
658		of septic shock: The CUB-Réa network, Am. J. Respir. Crit. Care Med. (2003).
659		doi:10.1164/rccm.2201087.
660	[37]	M. Coorens, M.R. Scheenstra, E.J.A. Veldhuizen, H.P. Haagsman, Interspecies
661		cathelicidin comparison reveals divergence in antimicrobial activity, TLR
662		modulation, chemokine induction and regulation of phagocytosis, Sci. Rep.
663		(2017). doi:10.1038/srep40874.
664	[38]	M. Lange, Y. Nakano, D.L. Traber, A. Hamahata, L.D. Traber, P. Enkhbaatar,
665		Time course of the inflammatory and oxidative stress response to pulmonary
666		infection in mice, Exp. Lung Res. (2012). doi:10.3109/01902148.2012.663453.
667	[39]	Y. Rosenfeld, N. Papo, Y. Shai, Endotoxin (lipopolysaccharide) neutralization by
668		innate immunity host-defense peptides: Peptide properties and plausible modes of
669		action, J. Biol. Chem. (2006). doi:10.1074/jbc.M504327200.
670	[40]	G.D. Amatngalim, A. Nijnik, P.S. Hiemstra, R.E.W. Hancock, Cathelicidin
671		peptide LL-37 modulates TREM-1 expression and inflammatory responses to
672		microbial compounds, Inflammation. (2011). doi:10.1007/s10753-010-9248-6.
673	[41]	M. Coorens, B.J.H. Banaschewski, B.J. Baer, C. Yamashita, A. van Dijk, H.P.
674		Haagsman, R.A.W. Veldhuizen, E.J.A. Veldhuizen, Killing of Pseudomonas
675		aeruginosa by chicken cathelicidin-2 is immunogenically silent, preventing lung

676		inflammation in vivo, Infect. Immun. (2017). doi:10.1128/IAI.00546-17.
677	[42]	E.M. Molhoek, A. van Dijk, E.J.A. Veldhuizen, H. Dijk-Knijnenburg, R.H.
678		Mars-Groenendijk, L.C.L. Boele, W.E. Kaman-van Zanten, H.P. Haagsman, F.J.
679		Bikker, Chicken cathelicidin-2-derived peptides with enhanced
680		immunomodulatory and antibacterial activities against biological warfare agents
681		Int. J. Antimicrob. Agents. (2010). doi:10.1016/j.ijantimicag.2010.06.001.
682	[43]	Y. Xiao, Y. Cai, Y.R. Bommineni, S.C. Fernando, O. Prakash, S.E. Gilliland, G.
683		Zhang, Identification and functional characterization of three chicken
684		cathelicidins with potent antimicrobial activity, J. Biol. Chem. (2006).
685		doi:10.1074/jbc.M507180200.
686	[44]	C. Gabay, C. Lamacchia, G. Palmer, IL-1 pathways in inflammation and human
687		diseases, Nat. Rev. Rheumatol. (2010). doi:10.1038/nrrheum.2010.4.
688		
689		
690		
691		
692		

HIGHLIGHTS

- Two novel AMPs P5 and P6.2 were analyzed in P.aeruginosa and S. aureus
- Scanning electron microscopy revealed distinct membranolytic activity
- Both peptides display in vitro antibiofilm activity
- Peptides diminished *P.aeruginosa* burden in the lungs of neutropenic mice
- P5 and P6.2 diminished lung pro-inflammatory cytokines